Do analysts prefer ZIVO or AKAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, ZIVO or AKAN?

ZIVO Bioscience has higher earnings, but lower revenue than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZIVO Bioscience $15.85K 1,257.39 -$7.78M -$1.71 N/A Akanda $258.08K 20.06 -$45.65M N/A N/A

Is ZIVO or AKAN more profitable?

Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Akanda N/A N/A N/A

Do analysts prefer TVGN or AKAN?

Tevogen Bio presently has a consensus target price of $100.00, indicating a potential upside of 2,167.57%. Given Tevogen Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Tevogen Bio is more favorable than Akanda. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, TVGN or AKAN?

Tevogen Bio has higher earnings, but lower revenue than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.61 N/A Akanda $258.08K 20.06 -$45.65M N/A N/A

Is TVGN or AKAN more profitable?

Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% Akanda N/A N/A N/A

Do analysts prefer VYNE or AKAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, VYNE or AKAN?

VYNE Therapeutics has higher revenue and earnings than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VYNE Therapeutics $454K 56.38 -$26.48M -$0.38 N/A Akanda $258.08K 20.06 -$45.65M N/A N/A

Do analysts rate CLRB or AKAN?

Cellectar Biosciences currently has a consensus price target of $11.00, suggesting a potential upside of 326.36%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Cellectar Biosciences is more favorable than Akanda. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, CLRB or AKAN?

Cellectar Biosciences has higher earnings, but lower revenue than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A Akanda $258.08K 20.06 -$45.65M N/A N/A

Is CLRB or AKAN more profitable?

Akanda's return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% Akanda N/A N/A N/A

Do analysts recommend AIXC or AKAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, AIXC or AKAN?

Qualigen Therapeutics has higher earnings, but lower revenue than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A Akanda $258.08K 20.06 -$45.65M N/A N/A

Is AIXC or AKAN more profitable?

Akanda's return on equity of 0.00% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% Akanda N/A N/A N/A

Akanda (AKAN) Competitors

$9.57 -0.43 (-4.30%)

Closing price 04:00 PM Eastern

Extended Trading

$9.76 +0.19 (+1.99%)

As of 06:13 PM Eastern

Compare

AKAN vs. ZIVO, TVGN, VYNE, CLRB, and AIXC

Should you buy Akanda stock or one of its competitors? MarketBeat compares Akanda with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akanda include ZIVO Bioscience (ZIVO), Tevogen Bio (TVGN), VYNE Therapeutics (VYNE), Cellectar Biosciences (CLRB), and Qualigen Therapeutics (AIXC). These companies are all part of the "pharmaceutical products" industry.

How does Akanda compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Akanda had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Akanda and 0 mentions for ZIVO Bioscience. Akanda's average media sentiment score of 1.15 beat ZIVO Bioscience's score of 0.00 indicating that Akanda is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Akanda	Positive

ZIVO Bioscience has higher earnings, but lower revenue than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,257.39	-$7.78M	-$1.71	N/A
Akanda	$258.08K	20.06	-$45.65M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Akanda	N/A	N/A	N/A

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ZIVO Bioscience has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market. Comparatively, Akanda has a beta of 14.06, indicating that its stock price is 1,306% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Akanda beats ZIVO Bioscience on 6 of the 10 factors compared between the two stocks.

How does Akanda compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Tevogen Bio and Tevogen Bio both had 2 articles in the media. Akanda's average media sentiment score of 1.15 beat Tevogen Bio's score of 0.93 indicating that Akanda is being referred to more favorably in the news media.

Company	Overall Sentiment
Tevogen Bio	Positive
Akanda	Positive

Tevogen Bio presently has a consensus target price of $100.00, indicating a potential upside of 2,167.57%. Given Tevogen Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Tevogen Bio is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Akanda	N/A	N/A	N/A

Tevogen Bio has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Akanda has a beta of 14.06, indicating that its stock price is 1,306% more volatile than the broader market.

Tevogen Bio has higher earnings, but lower revenue than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Akanda	$258.08K	20.06	-$45.65M	N/A	N/A

1.0% of Akanda shares are held by institutional investors. 70.5% of Tevogen Bio shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Akanda beats Tevogen Bio on 5 of the 9 factors compared between the two stocks.

How does Akanda compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, VYNE Therapeutics had 2 more articles in the media than Akanda. MarketBeat recorded 4 mentions for VYNE Therapeutics and 2 mentions for Akanda. Akanda's average media sentiment score of 1.15 beat VYNE Therapeutics' score of 1.15 indicating that Akanda is being referred to more favorably in the news media.

Company	Overall Sentiment
VYNE Therapeutics	Positive
Akanda	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Akanda has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. Akanda's return on equity of 0.00% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Akanda	N/A	N/A	N/A

VYNE Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Akanda has a beta of 14.06, suggesting that its stock price is 1,306% more volatile than the broader market.

VYNE Therapeutics has higher revenue and earnings than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$454K	56.38	-$26.48M	-$0.38	N/A
Akanda	$258.08K	20.06	-$45.65M	N/A	N/A

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by company insiders. Comparatively, 20.4% of Akanda shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

VYNE Therapeutics and Akanda tied by winning 6 of the 12 factors compared between the two stocks.

How does Akanda compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, Cellectar Biosciences had 12 more articles in the media than Akanda. MarketBeat recorded 14 mentions for Cellectar Biosciences and 2 mentions for Akanda. Cellectar Biosciences' average media sentiment score of 1.22 beat Akanda's score of 1.15 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectar Biosciences	Positive
Akanda	Positive

Cellectar Biosciences has higher earnings, but lower revenue than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Akanda	$258.08K	20.06	-$45.65M	N/A	N/A

Cellectar Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Akanda has a beta of 14.06, meaning that its share price is 1,306% more volatile than the broader market.

Akanda's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Akanda	N/A	N/A	N/A

Cellectar Biosciences currently has a consensus price target of $11.00, suggesting a potential upside of 326.36%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Cellectar Biosciences is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Cellectar Biosciences beats Akanda on 8 of the 13 factors compared between the two stocks.

How does Akanda compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and Akanda (NASDAQ:AKAN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Qualigen Therapeutics has higher earnings, but lower revenue than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Akanda	$258.08K	20.06	-$45.65M	N/A	N/A

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Akanda. MarketBeat recorded 3 mentions for Qualigen Therapeutics and 2 mentions for Akanda. Akanda's average media sentiment score of 1.15 beat Qualigen Therapeutics' score of 0.06 indicating that Akanda is being referred to more favorably in the news media.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Akanda	Positive

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 20.4% of Akanda shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Qualigen Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Akanda has a beta of 14.06, meaning that its stock price is 1,306% more volatile than the broader market.

Akanda's return on equity of 0.00% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Akanda	N/A	N/A	N/A

Summary

Akanda beats Qualigen Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Akanda News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKAN vs. The Competition

Export

Metric	Akanda	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.18M	$8.65B	$6.87B	$12.45B
Dividend Yield	N/A	2.56%	2.68%	9.44%
P/E Ratio	N/A	16.05	27.21	24.25
Price / Sales	20.06	6.31	510.54	87.39
Price / Cash	N/A	18.01	48.63	60.03
Price / Book	-0.37	3.31	10.78	6.23
Net Income	-$45.65M	$228.19M	$3.59B	$331.94M
7 Day Performance	-4.78%	-2.10%	-2.54%	-1.92%
1 Month Performance	-49.90%	-1.43%	2.81%	-0.96%
1 Year Performance	-89.47%	-0.74%	25.42%	18.25%

Akanda Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKAN Akanda	1.3517 of 5 stars	$9.57 -4.3%	N/A	-89.0%	$5.18M	$258.08K	N/A	110	Positive News
ZIVO ZIVO Bioscience	N/A	$5.25 flat	N/A	-67.3%	$21.80M	$15.85K	N/A	10	Gap Up
TVGN Tevogen Bio	1.8483 of 5 stars	$5.20 -5.5%	$100.00 +1,823.1%	-92.0%	$21.79M	N/A	N/A	3
VYNE VYNE Therapeutics	1.5807 of 5 stars	$0.65 -2.9%	N/A	-41.3%	$21.68M	$570K	N/A	30	Positive News Dividend Announcement
CLRB Cellectar Biosciences	4.2884 of 5 stars	$2.69 -0.4%	$11.00 +308.9%	-45.4%	$21.50M	N/A	N/A	10	News Coverage Positive News Short Interest Increase Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKAN) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akanda (AKAN) Competitors

AKAN vs. ZIVO, TVGN, VYNE, CLRB, and AIXC

How does Akanda compare to ZIVO Bioscience?

Summary

How does Akanda compare to Tevogen Bio?

Summary

How does Akanda compare to VYNE Therapeutics?

Summary

How does Akanda compare to Cellectar Biosciences?

Summary

How does Akanda compare to Qualigen Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKAN vs. The Competition

Akanda Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akanda (AKAN) Competitors

AKAN vs. ZIVO, TVGN, VYNE, CLRB, and AIXC

How does Akanda compare to ZIVO Bioscience?

Does the media prefer ZIVO or AKAN?

Which has preferable valuation and earnings, ZIVO or AKAN?

Is ZIVO or AKAN more profitable?

Do insiders and institutionals believe in ZIVO or AKAN?

Which has more risk & volatility, ZIVO or AKAN?

Do analysts prefer ZIVO or AKAN?

Summary

How does Akanda compare to Tevogen Bio?

Does the media prefer TVGN or AKAN?

Do analysts prefer TVGN or AKAN?

Is TVGN or AKAN more profitable?

Which has more risk & volatility, TVGN or AKAN?

Which has preferable valuation and earnings, TVGN or AKAN?

Do insiders and institutionals believe in TVGN or AKAN?

Summary

How does Akanda compare to VYNE Therapeutics?

Does the media refer more to VYNE or AKAN?

Do analysts prefer VYNE or AKAN?

Is VYNE or AKAN more profitable?

Which has more risk and volatility, VYNE or AKAN?

Which has preferable earnings & valuation, VYNE or AKAN?

Do insiders & institutionals hold more shares of VYNE or AKAN?

Summary

How does Akanda compare to Cellectar Biosciences?

Does the media prefer CLRB or AKAN?

Which has stronger valuation and earnings, CLRB or AKAN?

Which has more risk & volatility, CLRB or AKAN?

Is CLRB or AKAN more profitable?

Do analysts rate CLRB or AKAN?

Do insiders and institutionals have more ownership in CLRB or AKAN?

Summary

How does Akanda compare to Qualigen Therapeutics?

Do analysts recommend AIXC or AKAN?

Which has better earnings and valuation, AIXC or AKAN?

Does the media refer more to AIXC or AKAN?

Do insiders & institutionals have more ownership in AIXC or AKAN?

Which has more volatility and risk, AIXC or AKAN?

Is AIXC or AKAN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKAN vs. The Competition

Akanda Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools